(Q37780346)

23 August 2017

1 reference

title

Principles of vaccine design-Lessons from nature (English)

1 reference

23 August 2017

1 reference

1 reference

Fred Zepp

1

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 August 2010

1 reference

23 August 2017

1 reference

23 August 2017

volume

28 Suppl 3

1 reference

23 August 2017

page(s)

C14-24

1 reference

Key concepts in immunology

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Vaccines: conquering untreatable diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

A review of vaccine research and development: human enteric infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Japanese encephalitis vaccines--needs, flaws and achievements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Vaccines for preventing tick-borne encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Measles: old vaccines, new vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

The development of live attenuated cold-adapted influenza virus vaccine for humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Hepatitis B vaccine -- do we need boosters?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Vaccines for preventing typhoid fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Rational design of conjugate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Design and development of synthetic peptide vaccines: past, present and future

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Vaccines against cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Virus-like particles as a vaccine delivery system: myths and facts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Vaccinology in the genome era.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Reverse vaccinology and vaccines for serogroup B Neisseria meningitidis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

(How) do aluminium adjuvants work?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Unmet needs in modern vaccinology: adjuvants to improve the immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Immunostimulatory DNA as a vaccine adjuvant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

TLR4 agonists as immunomodulatory agents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Papillomaviruses and cancer: from basic studies to clinical application

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Influenza vaccine: the challenge of antigenic drift.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Anti-immunology: evasion of the host immune system by bacterial and viral pathogens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Strategies for the development of vaccines conferring broad-spectrum protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Current status and progress of prepandemic and pandemic influenza vaccine development.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

The immunological challenges of malaria vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Neonatal and infantile immune responses to encapsulated bacteria and conjugate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

The challenges of vaccine responses in early life: selected examples

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Immunosenescence and vaccine failure in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Why aging T cells fail: implications for vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Age-associated change in the frequency of memory CD4+ T cells impairs long term CD4+ T cell responses to influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Evasion and subversion of antigen presentation by Mycobacterium tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

New vaccines for tuberculosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

The dream of a vaccine against tuberculosis; new vaccines improving or replacing BCG?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

The potential impact of a prophylactic herpes simplex vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Herpes Simplex: Insights on Pathogenesis and Possible Vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

The role of toll-like receptor ligands/agonists in protection against genital HSV-2 infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Understanding HSV-1 entry glycoproteins.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Use of attenuated bacteria as delivery vectors for DNA vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Use of viral vectors for the development of vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Scientific and policy challenges to development of an AIDS vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Patterns of antigenic diversity and the mechanisms that maintain them

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Antigen-specific T-cell-mediated immunity after HIV-1 infection: implications for vaccine control of HIV development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Viral vectors in malaria vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

DNA vaccines: are they still just a powerful tool for the future?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Recent advance in immunotherapies for Alzheimer disease: with special reference to DNA vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Immune therapy for cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Immunotherapy of distant metastatic disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth f

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Immunomodulation of allergic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

Recent advances in DNA vaccines for autoimmune diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

inferred from DOI database lookup

7 January 2021

based on heuristic

Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.07.020

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2010.07.020

1 reference

23 August 2017

1 reference